A Randomized, Double-Blind, Placebo-Controlled Escalating Dose Phase I Interaction Study to Evaluate the Pharmacokinetics, Tolerability and Pharmacodynamics of Three Dose Levels of Debio 0614 (Istaroxime) as a 24-Hour Constant Rate IV Infusion in Combination With Chronic Oral Digoxin Treatment in Patients With Controlled Cardiac Failure and Decreased Left Ventricular Systolic Function.
Latest Information Update: 01 Dec 2014
Price :
$35 *
At a glance
- Drugs Istaroxime (Primary) ; Digoxin
- Indications Heart failure; Left ventricular dysfunction
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Debiopharm
- 04 Nov 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 07 Apr 2009 New trial record